Congenital insensitivity to pain

Template:Infobox medical condition Congenital insensitivity to pain (CIP), also known as congenital analgesia, is an inability for a person to feel physical pain due to various rare genetic conditions. CIP is caused by genetic mutations that affect the development or function of nociceptors, the sensory neurons in the brain responsible for recognizing tissue damage. Common symptoms include damage to the oral cavity, repeated bone fractures, and sometimes the inability to sweat. Some forms of CIP are also correlated with intellectual disabilities, learning disabilities, or attention deficit hyperactivity disorder (ADHD). Hereditary sensory autonomic neuropathies (HSAN) fall under the umbrella of CIP. Methods of treatment are still being explored. The epidemiology of CIP is unclear, given the relatively low number of reported cases.

Classification

The term congenital analgesia, also known as CIP, was first coined in the 1970s or 1980s.<ref name=":0">Template:Cite journal</ref> CIP is an umbrella term that describes a collection of rare genetic disorders that affect nerve tissue in either the peripheral or autonomic nervous systems.<ref name=":0" /> When genetic disorders interfere with nociceptors, an individual develops CIP.<ref name=":0" /><ref name=":2">Template:Cite journal</ref> A 2019 paper argues that "congenital insensitivity to pain" is a misnomer, and theorizes that patients might still feel other (non-nociceptive) forms of pain, even if they are unable to accurately classify such sensations.<ref name=":0" /> The paper suggests "congenital nociceptor deficiency" as a possible alternative term.<ref name=":0" /> There are 5 types of HSAN that are classified as CIP disorders.<ref name=":0" /> As of 2025, the HSAN disorders are still classified using a system developed by Dyck P. J. in 1984.<ref name=":0" />

Signs and symptoms

For people with this disorder, cognition and sensation are otherwise normal; for instance, patients can still feel discriminative touch (though not always temperature), and there are generally no detectable physical abnormalities.<ref name=":0" /><ref>Template:OMIM</ref> Congenital insensitivity to pain with anhidrosis (CIPA) is a kind of CIP categorized by patients' inability to sweat (also known as HSAN-IV).<ref name=":0" /><ref name=":1">Template:Citation</ref> The inability to regulate internal temperature can lead to unexplained persistent fevers.<ref name=":1" />

Because children and adults with CIP cannot perceive pain, they may not respond to pain-inducing stimuli, putting them at a high risk for infections and complications resulting from injuries.<ref name="Hellier">Template:Cite book</ref> Children with this condition often sustain self-inflicted damage, both in and around the oral cavity (such as having bitten off the tip of their tongue) or fractures to bones.<ref name="Hellier" /> Repeated bone fractures can lead to improper healing, potentially resulting in permanent joint damage, or in severe cases, Charcot joints.<ref name=":1" /><ref name=":3">Rodríguez-Blanque, Raquel, et al. "A Systematic Review of Congenital Insensitivity to Pain, a Rare Disease." Journal of Personalized Medicine 14.6 (2024)ProQuest Central. Web.</ref> Many young children also present with persistent ear infections and damaged fingertips due to biting.<ref name=":1" /> Unnoticed infections and corneal damage due to foreign objects in the eye are also common.<ref name="Hellier" /><ref name=":1" /><ref name="Brodsky2">Template:Cite book</ref> Particular strains of CIP put individuals at a higher risk for developing Staphylococcus aureus infections.<ref name=":2" /><ref name=":1" /> Depending on the genetic cause of CIP, individuals may be intellectually impaired and may have conditions such as ADHD.<ref name=":1" /> The degree of the effect of CIP on the intellectual impairment of an individual has to do with the location of the mutation on the affected gene.<ref name=":3" /> The life expectancy of individuals with CIP is shorter than normal life expectancy.<ref name=":0" />

There are generally two types of CIP:

• Nociceptors do not develop, meaning that painful stimulus is not even perceived.<ref name="Linton">Template:Cite book</ref><ref name=":2" /> These are also known as the HSAN disorders.<ref name=":2" />
• Nociceptors develop but do not respond to tissue signals, meaning that the patient can perceive the stimulus, but lacks an appropriate response.<ref name=":2" /><ref name="Brodsky2" />

Causes

CIP is caused by extremely rare genetic disorders.<ref name=":2" /> Roughly 50% of CIP cases are inherited from a parent with CIP.<ref name=":3" /> Of the five HSAN disorders, HSAN II, III, IV, and V are inherited via an autosomal recessive pattern, while HSAN I is inherited via an autosomal dominant pattern.<ref name=":0" /> The breakdown of specific genetic mutation types among those diagnosed with CIP is unknown as of 2020.<ref name=":1" /> HSAN IV, one of the more common forms of CIP, is caused by a mutation in the NTRK1 gene (also known as TrkA).<ref name=":1" />

Case studies

Various case studies have demonstrated how specific genetic mutations have led to CIP. In all cases, this disorder can be in the voltage-gated sodium channel SCN9A (Na_v1.7).<ref>Template:Cite journal</ref> There are three mutations in SCN9A: W897X, located in the P-loop of domain 2; I767X, located in the S2 segment of domain 2; and S459X, located in the linker region between domains 1 and 2.<ref name="Cox_20062">Template:Cite journal</ref> This results in a truncated non-functional protein.<ref name="Cox_20062" /> Na_v1.7 channels are expressed at high levels in nociceptive neurons of the dorsal root ganglia.<ref name="Cox_20062" /> As these channels are likely involved in the formation and propagation of action potentials in such neurons, it is expected that a loss-of-function mutation in SCN9A leads to abolished nociceptive pain propagation.<ref name="Cox_20062" /><ref>Template:Cite journal</ref>

The PRDM12 gene is normally switched on during the development of pain-sensing nerve cells.<ref name=":4">Template:Cite journal</ref> People with homozygous mutations of the PRDM12 gene experience congenital insensitivity to pain (CIP).<ref name=":4" /><ref name="Uncomfortably numb: The people who feel no pain2">Template:Cite news</ref>

Another gene implicated in human pain insensitivity is ZFHX2, which encodes zinc finger homeobox 2.<ref name=":5">Template:Cite journal</ref> A 2018 study analyzed six members of a family with inherited pain insensitivity and identified a "novel point mutation in ZFHX2, encoding a putative transcription factor expressed in small diameter sensory neurons" as the cause.<ref name=":5" /> As a therapeutic application, the study further discusses how "the ZFHX2 variant and downstream regulated genes associated with a human pain-insensitive phenotype are ... potential novel targets for the development of new analgesic drugs".<ref name=":5" />

Jo Cameron is an example of one individual known to have congenital analgesia. She has two mutations, one in the gene encoding fatty acid amide hydrolase (FAAH) and one in the pseudogene FAAH-OUT modulating FAAH expression, which are theorized to be responsible for her condition.<ref name="AhmedBoileauLeFoll2022" /><ref name="MikaeiliHabibYeung2023" /><ref name="Levy2020" /><ref name="HabibOkorokovHill2019" /> FAAH is an enzyme involved in the metabolism of endocannabinoids like anandamide.<ref name="Fowler2021" /><ref name="SantosoDeRidder2023" /><ref name="MaccarroneDiMarzoGertsch2023" /><ref name="Levy2020" /><ref name="HabibOkorokovHill2019" /> Cameron has high levels of anandamide and other endocannabinoids.<ref name="AhmedBoileauLeFoll2022">Template:Cite journal</ref><ref name="Levy2020" /><ref name="HabibOkorokovHill2019" />

Treatment

As of 2020, there is no agreed-upon method in the medical community for treating CIP.<ref name=":1" /> Treatment plans involve injury management and prevention.<ref name=":3" /> In an experimental trial, an opioid antagonist, naloxone, allowed a woman with CIP to experience pain for the first time.<ref name="MinettPereira20152">Template:Cite journal</ref> This result revealed that opioid antagonists like naloxone and naltrexone may be effective in treating CIP in the future.<ref name="MinettPereira20152" /> Additionally, the genes that cause CIP provide promising targets for novel pain medications, also known as analgesics.<ref name=":2" />

Epidemiology

A 2020 estimate places the incidence of CIP as one person in a million. Based on the observation that under thirty cases are known in the United Kingdom.<ref name=":0"/><ref name=":1"/> CIP is found at an abnormally high frequency in Vittangi, a village in Kiruna Municipality in northern Sweden, where nearly 40 cases have been reported.<ref>Template:Cite journal</ref>

See also

• Pain asymbolia

External links

• "The Hazards of Growing Up Painlessly" by Justin Heckert, The New York Times Magazine, November 15, 2012. Profile of Ashlyn Blocker, 13, who has congenital insensitivity to pain.